Founded in 2019 and based in White Plains, New York, Iantrek is dedicated to developing cutting-edge technology for minimally invasive microinvasive glaucoma surgery (MIGS). The company's core mission is to revolutionize glaucoma treatment by providing innovative surgical solutions that improve patient outcomes and reduce recovery times. Iantrek's vision is to become a leader in the ophthalmic medical device industry, offering advanced products that address the unmet needs of glaucoma patients and healthcare providers.
Iantrek has attracted notable investors and industry experts who support its mission to advance MIGS technology. The company has achieved significant milestones, including the development and successful testing of its proprietary surgical devices. Iantrek's impact on the field of glaucoma treatment is marked by its commitment to innovation and improving the quality of life for patients suffering from this condition.
